Why the study?
Does E-4031 alter myocardial contractility and electrophysiological parameters in guinea pig cardiac preparations?
Does E-4031 alter myocardial contractility and electrophysiological parameters in guinea pig cardiac preparations?
E-4031 acts as a class III antiarrhythmic by selectively reducing outward currents, which prolongs action potential duration and enhances contractility in guinea pig cardiac preparations.
Answers are grounded in this paper and cite their sources.
Supports class III effects in guinea pig models; leaves open clinical translation and safety.
The effects of the new class III antiarrhythmic agent E-4031 were investigated in different guinea pig cardiac preparations. In left atria, E-4031 (10(-8)-10(-5) M) prolonged the functional refractory period up to 45% and reduced the frequency of spontaneously beating right atria by 32%. In papillary muscles, E-4031 (3 x 10(-8)-3 x 10(-7) M) reversibly prolonged the action potential duration (APD70) of fast and slow APs by 68 and 51%, respectively. Vmax, resting potential, and AP amplitude (APA) were not altered. In isolated ventricular myocytes, E-4031 reversibly prolonged the APD90 from 275 ms (control) to 1,496 ms (10(-6) M), pD2 value 6.5. The current changes that underlie the AP-prolonging effect were also studied in ventricular myocytes: in concentrations up to 10(-5) M), E-4031 did not affect the Na+ or Ca2+ inward current but reduced the delayed rectifier (IK) tail current by 76% (10(-7) M). Contractility was enhanced by E-4031 in isolated atria by 20% (3 x 10(-7) M) and increased cell shortening in ventricular myocytes. Thus, the class III antiarrhythmic action of E-4031 is due to a selective reduction of outward currents.
No takes yet. Share an insight, caveat, or question.
Wettwer et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: